On the occasion of the sale of Cyclopharma to Curium in December 2018, its management team took over the development projects of the most innovative molecules from Cyclopharma’s pipeline and created Zionexa.

Zionexa is a radiopharmaceutical company specializing in the research, development and commercialization of molecular imaging solutions, companions to targeted therapies in oncology.

Zionexa’s objective is to complete the development of these molecules, to ensure their registration and access to the French and international markets, particularly in the US. Zionexa’s first product is EstroTep, a diagnostic tool for breast cancer. This innovative, non-invasive technology for tracing and characterizing cancer cells reduces the number of biopsies, which are always traumatic, and allows the company to verify that the therapy chosen to treat the disease is the right one.

Interest sold in 2021.